Introduction
Metal complexes offer vast opportunities for the design of compounds with bioactivity due to the large variety of avail-able metals and the ability to tune the reactivity and structure of the metal complexes by their ligand spheres. [1] Most commonly, the metal is directly involved in the mode of action, either through coordination or redox chemistry. For example, the highly successful anticancer drug cisplatin (1) crosslinks guanine bases in DNA duplexes. [2] Similarly, the ruthenium arene complex 2 and its derivatives exert their highly cytotoxic effects through coordination to DNA, [3] whereas the ferrocene moiety in the breast cancer drug candidate hydroxyferrocifen (3) is believed to serve as a crucial redox-active moiety. [4] Thus, these reactive anticancer drugs require a fine-tuned reactivity of the metal center, and it is, therefore, not surprising that in these complexes a substitution of the metal by one of their homologues results in a decline in anticancer activities: the palladium analogue of cis-Abstract: In this study, we probe and verify the concept of designing unreactive bioactive metal complexes, in which the metal possesses a purely structural function, by investigating the consequences of replacing ruthenium in a bioactive half-sandwich kinase inhibitor scaffold by its heavier congener osmium. The two isostructural complexes are compared with respect to their anticancer properties in 1205 Lu melanoma cells, activation of the Wnt signaling pathway, IC 50 values against the protein kinases GSK-3b and Pim-1, and binding modes to the protein kinase Pim-1 by protein crystallography. It was found that the two conge-ners display almost indistinguishable biological activities, which can be explained by their nearly identical threedimensional structures and their identical mode of action as protein kinase inhibitors. This is a unique example in which the replacement of a metal in an anticancer scaffold by its heavier homologue does not alter its biological activity.
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